Sep 2019 $2 M No. 5 $2 to $10 million 37
Carmell Therapeutics Corp: Raise no. 5, Sep 2019 × Investors in this round 37 investors had bought by the notice of Sep 25, 2020: 37 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $4 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions $37,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Donna Godward · Executive Officer James Hart · Executive Officer Randolph Hubbell · Executive Officer, Director Stephanie W. Kladakis · Executive Officer David W. Anderson · Director Richard Upton · Director Wendy W. DiCicco · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Alere Financial Partners (CRD 109761) · Syosset, New York Sold in all US states Remarks in the notice On the amounts: “Offering consists of $3,200,000 of Convertible Notes and $300,000 of Warrants”Signed by Randolph W. Hubbell, Chief Executive Officer and President. Source: SEC Form D, newest notice filed Sep 25, 2020. Read the notice at the SEC .
debt, options SEC Jul 2018 $5 M No. 4 $2 to $10 million 44
Carmell Therapeutics Corp: Raise no. 4, Jul 2018 × Investors in this round 44 investors had bought by the notice of Mar 14, 2019: 44 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $8 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $855,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Donna Godward · Executive Officer James Hart · Executive Officer Randolph Hubbell · Executive Officer, Director Stephanie W. Kladakis · Executive Officer David W. Anderson · Director James F. Jordan · Director Richard Upton · Director Wendy W. DiCicco · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Dalmore Group, LLC (CRD 136352) · Woodmere, New York Sold in AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY Remarks in the notice On fees: “Represents up to 9% placement agent fee.”Signed by Randolph W. Hubbell, Chief Executive Officer and President. Source: SEC Form D and 1 amendment, newest notice filed Mar 14, 2019. Read the notice at the SEC .
debt, options SEC Sep 2017 $2 M No. 3 Under $2 million 25
Carmell Therapeutics Corp: Raise no. 3, Sep 2017 × Investors in this round 25 investors had bought by the notice of Dec 6, 2017: 25 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered; $0 M still to sell
Smallest investment taken $3,741
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Donna Godward · Executive Officer James Hart · Executive Officer Randolph Hubbell · Executive Officer, Director Stephanie W. Kladakis · Executive Officer David W. Anderson · Director James F. Jordan · Director Richard Upton · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Randolph W. Hubbell, Chief Executive Officer and President. Source: SEC Form D, newest notice filed Dec 6, 2017. Read the notice at the SEC .
equity SEC Dec 2016 $1 M No. 2 Under $2 million 25
Carmell Therapeutics Corp: Raise no. 2, Dec 2016 × Investors in this round 25 investors had bought by the notice of Apr 14, 2017: 25 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $2 M offered; $1 M still to sell
Smallest investment taken $10,000
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Donna Godward · Executive Officer James Hart · Executive Officer Randolph Hubbell · Executive Officer, Director Stephanie W. Kladakis · Executive Officer David W. Anderson · Director James F. Jordan · Director Richard Upton · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Randolph Hubbell, Chief Executive Officer and President. Source: SEC Form D, newest notice filed Apr 14, 2017. Read the notice at the SEC .
equity, options SEC Apr 2011 $2 M No. 1 $2 to $10 million 9
Carmell Therapeutics Corp: Raise no. 1, Apr 2011 × Investors in this round 9 investors had bought by the notice of Apr 13, 2011: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $3 M offered; $1 M still to sell
Smallest investment taken $25,000
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Alan I. West · Executive Officer, Director J. Michael Egan · Director James Michael Jordan · Director Paul Michael Kornblith · Director Richard Michael Upton · Director William Michael Newlin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Alan I. West, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 13, 2011. Read the notice at the SEC .
equity SEC